07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

Cebix management update

Cebix Inc., La Jolla, Calif.   Business: Endocrine/Metabolic   Hired: Joel Martin as president and CEO, formerly president and CEO of Altair Therapeutics Inc., which an undisclosed company acquired   ...
00:57 , Oct 18, 2012 |  BC Extra  |  Financial News

Cebix raises $21.3M, names Martin CEO

Cebix Inc. (La Jolla, Calif.) raised $21.3 million in a series B round and hired Joel Martin as president and CEO. Martin is formerly president and CEO of asthma company Altair Therapeutics Inc., which was...
07:00 , Aug 15, 2011 |  BioCentury  |  Product Development

Locking in lebrikizumab

In the race to treat asthma by blocking IL-13, Genentech Inc. now has positive Phase II data and a biomarker for responders to lebrikizumab in severe asthma patients. Next up is data from MedImmune LLC's...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Altair Therapeutics inflammation, pulmonary news

Former partner Isis Pharmaceuticals Inc. (NASDAQ:ISIS, Carlsbad, Calif.) confirmed that Altair ceased operations. The biotech declined to disclose further details. Altair was formed in 2007 by Thomas, McNerney & Partners to discover, develop and...
07:00 , Jul 22, 2010 |  BC Innovations  |  Targets & Mechanisms

Something against TIM-1 in asthma

Researchers at Biogen Idec Inc. and colleagues have used a humanized mouse model to show that inhibiting T cell immunoglobulin and mucin domain 1 could help treat allergic asthma.1 The findings are the first to...
08:00 , Feb 8, 2010 |  BioCentury  |  Emerging Company Profile

Altair: Breathing easier with antisense

Several compounds in development to treat asthma have been designed to modify the underlying disease by inhibiting or disrupting the inflammatory activity of the cytokines IL-4 and IL-13. So far, compounds targeting one or the...
08:00 , Feb 8, 2010 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Altair Therapeutics Inc. San Diego, Calif. Technology: Inhaled antisense molecule targeting IL-4 receptor (CD124) subunit alpha Disease focus: Inflammation Clinical status: Phase IIa Founded: 2007 by Susan Gregory and Pratik Shah University collaborators: None Corporate partners: None Number of employees: 7 Funds raised: Not...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

AIR645: Phase IIa started

Altair began the double-blind, placebo-controlled, Canadian Phase IIa AIR465- CR2 trial in 30 patients to evaluate inhaled AIR645 vs. placebo. Altair Therapeutics Inc., San Diego, Calif.   Product: AIR645   Business: Inflammation   Molecular target: NA   Description: 2'-O-methoxyethyl...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Financial News

Altair Therapeutics completes venture financing

Altair Therapeutics Inc., San Diego, Calif.   Business: Inflammation   Date completed: 11/11/09   Type: Venture financing   Raised: $17 million   Investors: Domain Associates; AgeChem Venture Fund; Thomas, McNerney & Partners; Forward Ventures; Isis Pharmaceuticals Inc.   ...
01:10 , Nov 12, 2009 |  BC Extra  |  Financial News

Altair raises $17 million

Altair Therapeutics Inc. (San Diego, Calif.) raised $17 million in a series A round led by new investor Domain Associates. AgeChem Venture Fund, also a new investor, joined existing investors Thomas, McNerney; Forward Ventures; and...